Clearside Biomedical’s (CLSD) Buy Rating Reiterated at Chardan Capital
Chardan Capital reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research note published on Friday morning,Benzinga reports. Chardan Capital currently has a $6.00 target price on the stock. Several other research firms have also commented on CLSD. StockNews.com lowered shares of Clearside Biomedical from a “hold” rating to […]
Chardan Capital reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research note published on Friday morning,Benzinga reports. Chardan Capital currently has a $6.00 target price on the stock. Several other research firms have also commented on CLSD. StockNews.com lowered shares of Clearside Biomedical from a “hold” rating to […]
